A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE)

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Evobrutinib (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors EMD Serono
  • Most Recent Events

    • 05 Oct 2017 Planned number of patients changed from 468 to 451.
    • 18 Aug 2017 Planned number of patients changed from 432 to 468.
    • 18 Aug 2017 Planned End Date changed from 10 Jan 2020 to 31 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top